GlassScriptPhysician profile
Philip J Proctor
NPI 1871685339
$8,088.53
in general payments reported to CMS, 2019-2025
39 companies · $1,669 in 2025
The $1,669 reported for 2025 was more than what 75% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $203 · 2020: $1,669 · 2021: $1,202 · 2022: $1,189 · 2023: $1,303 · 2024: $854 · 2025: $1,669.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,825.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,825.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,211.79 | 2020-2025 | Erleada, Rybrevant, Carvykti |
| Astellas Pharma US INC | $924.96 | 2019-2025 | Xtandi, Myrbetriq, Veozah |
| E.R. Squibb & Sons, L.L.C. | $924.74 | 2020 | |
| Sumitomo Pharma America, INC. | $576.06 | 2023-2025 | Orgovyx, Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $522.26 | 2020-2025 | |
| Endo Pharmaceuticals INC. | $418.43 | 2019-2024 | Xiaflex, Edex, Aveed |
| Dendreon Pharmaceuticals LLC | $340.12 | 2019-2024 | Provenge |
| Tolmar, INC. | $320.01 | 2023-2025 | Eligard, Jatenzo |
| Abbvie INC. | $298.50 | 2020-2025 | |
| Janssen Pharmaceuticals, INC | $286.49 | 2021-2025 | Erleada |
| Pfizer INC. | $250.83 | 2020-2025 | |
| Tolmar Pharmaceuticals, INC. | $191.91 | 2019-2022 | |
| Acerus Pharmaceuticals Corporation | $182.90 | 2020-2022 | |
| Urovant Sciences INC | $177.36 | 2021-2022 | |
| Endo USA, INC. | $169.61 | 2024-2025 | Aveed, Xiaflex, Edex |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $166.43 | 2020-2024 | Xyosted |
| Myovant Sciences INC. | $140.36 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $87.95 | 2025 | |
| Accord Healthcare, INC. | $83.71 | 2022-2023 | |
| Alnylam Pharmaceuticals INC. | $71.10 | 2021-2022 | |
| Laborie Medical Technologies Corp. | $68.23 | 2023-2025 | Optilume Bph Drug Coated Balloon Catheter, Endosheath Technology |
| 180 Medical, INC. | $64.77 | 2020-2024 | |
| Myriad Genetic Laboratories, INC. | $64.45 | 2021-2022 | |
| Ferring Pharmaceuticals INC. | $59.72 | 2024-2025 | Adstiladrin |
| Olympus America INC. | $56.28 | 2021-2023 | Itind System |
| Blue Earth Diagnostics | $53.99 | 2021-2023 | |
| Amgen INC. | $53.02 | 2019-2021 | |
| Boston Scientific Corporation | $49.49 | 2021-2025 | Axonics |
| Merck Sharp & Dohme LLC | $43.46 | 2023 | Lynparza, Keytruda, Welireg |
| Allergan, INC. | $35.35 | 2019-2020 | |
| Clarus Therapeutics INC. | $30.84 | 2021 | |
| Convatec INC. | $28.45 | 2021 | |
| Azurity Pharmaceuticals, INC. | $24.96 | 2025 | Azmiro |
| Bioprotect Medical, INC. | $24.82 | 2025 | Bioprotect Balloon Implant System |
| Clovis Oncology, INC. | $21.20 | 2020 | |
| Telix Pharmaceuticals | $19.98 | 2024 | Illuccix |
| Axonics, INC. | $16.26 | 2022 | |
| Genzyme Corporation | $15.24 | 2021 | |
| Medtronic, INC. | $12.50 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Proctor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.